INTRODUCTION

Myocardial infarction (MI) mainly refers to ischemic myocardial necrosis. It is due to narrowing or blockage of the coronary arteries that results in drastically reduced or interrupted coronary blood flow. The lack of blood flow and oxygen to the heart muscle cause lasting severe myocardial ischemia, which eventually leading to ischemic myocardial necrosis. Myocardial infarction generally accompanied with varying degrees of impairment of ventricular function. Clinically, patients with myocardial infarction are present with systemic symptoms, such as intense and lasting chest pain, tissue necrosis, acute circulatory failure, shock, heart failure or severe cardiac arrhythmias that can cause sudden death.

TRADITIONAL TREATMENT

At present, the treatments of myocardial infarction mainly focus on the recanalization of the occluded coronary artery to restore perfusion and prevent myocardial necrosis. To do this, commonly used methods include drug therapy, thrombolytic therapy, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) surgery.

Drug therapies
Traditional drug therapies include angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone receptor antagonists, β-receptor blockers, and so on [1-3]. The main purpose of these treatments is the prevention of left ventricular remodeling.

Thrombolytic therapy
Thrombolytic therapy is presently the main approach for the treatment of myocardial infarction. Principles of thrombolytic...
therapy in treating acute myocardial infarction are recanalization of the occluded coronary artery and restoration of the perfusion as soon as possible.

A large number of clinical studies indicated that thrombolytic therapy that taken within 6 hours after the onset of myocardial infarction achieved the best curative effect, and the earlier treatment is started, the better the curative effect[10].

Biochemical and clinical trials have proved that thrombosis and thrombolysis are dynamic processes occurring simultaneously. Inhibition of thrombus formation will accelerate the dissolution of blood clots[11]. Currently, the most commonly used thrombolytic drugs are streptokinase, urokinase and tissue-type plasminogen activators[12-14]. These thrombolytic drugs work well in the dissolution of blood clots but have some side-effects, mainly including unwanted bleeding, such as mucosal bleeding, subcutaneous bleeding, or life-threatening intracerebral hemorrhage. Nevertheless, there was only one-third of patients with myocardial infarction met the requirements for thrombolytic therapy.

Percutaneous coronary intervention
Take the limitations of thrombolytic therapy into consideration, percutaneous coronary intervention (PCI) has gradually become another choice to restore perfusion. This procedure effectively restores the blood flow and recovers the function of heart muscle by inserting a special catheter into a blood vessel and inflated at the narrowed area of the coronary artery[15]. Compared with thrombolytic therapy, PCI removes the thrombus and the reperfusion rate after the intervention is 95% to 99%. But PCI also has some possible risks, such as bleeding or infection at the catheter insertion site, allergic reaction to the contrast dye used, blood clot within the treated blood vessel, rupture of the coronary artery, and complete closing of the coronary artery.

Coronary artery bypass grafting
Coronary artery bypass grafting (CABG) is an effective surgical treatment of coronary heart disease and myocardial ischemia, which can effectively relieve symptoms. It is also an effective method for the treatment of restenosis and acute complications in patients after PCI. Once the acute complications occur after surgery, emergency CABG will minimize myocardial damage and reduce hospital mortality and adverse events[16]. Therefore, CABG is an important alternative or combination therapy to PCI.

Although drug therapy, thrombolytic therapy, percutaneous coronary intervention and coronary artery bypass graft surgery can to some extent prevent ventricular remodeling and relieve the symptoms of myocardial ischemia. But these treatments cannot repair the necrotic myocardial tissue and solve the fundamental problem of myocardial infarction. How to promote the regeneration of necrotic cardiomyocytes and prevent ventricular remodeling has become the key to improving the cardiac function after myocardial infarction. Therefore, in recent years, myocardial regeneration has become the hotspot of cardiovascular research. And it is also the new treatment of myocardial infarction in this review.

NEW STRATEGIES
Cardiomyocytes are traditionally considered as terminally differentiated cells. Once the cardiomyocyte is damaged, it will not be able to regenerate. In myocardial infarction, the dead myocardial cells were replaced by fibroblasts, which eventually leading to ventricular remodeling and heart failure. The discovery of stem cells makes the regeneration of cardiomyocyte possible. Animal experiments showed that stem cell transplantation can contribute to the regeneration of cardiomyocyte and improve cardiac function[17,18]. Some of the stem cell types are being applied in clinical trials to prove it an acceptable and applicable treatment in human[19,20]. There are two main types of stem cells used in myocardium regeneration, pluripotent stem cells including embryonic stem cells (ESC) and induced pluripotent stem cells (iPSCs), and adult stem cells including mesenchymal stem cells, skeletal muscle myoblast cardiac stem cells (CSC) and bone marrow cells (BMC) (Figure 1).

Embryonic stem cells
Embryonic stem cells (ESC) are pluripotent cells that can differentiate into a variety of cell types, including cardiomyocyte. It has been extensively investigated for the repair of the infarcted heart. Studies in animal models have shown promising effects of embryonic stem cell-derived cardiomyocytes (ESC-CMs) treatment[13,14]. Transplantation of human ESC-CMs in a non-human primate (NHP) model of myocardial ischemia-reperfusion showed evident remasculinization, but potential arrhythmic complications remain unsolved[15]. Currently, there are four major reasons that hinder the clinical application of ESC: Firstly, the transplanted embryonic stem cells may differentiate into unwanted cell types in the human body. As a great many of cardiomyocytes are lost after a typical infarct[16], complete repair of the heart requires large-scale production of ESC-CMs. While the feasibility of this large-scale committed differentiation of ESC in the human heart is not clear. Secondly, the immune system of a person may see the transplanted cells as foreign and reject them by aggressive immune response[17]. Thirdly, stem cells may undergo a carcinogenic transformation, which means transplant recipients bear the risk for tetraloma formation[18]. Lastly, ethical concerns related to embryonic stem cell research limits the collection and usage of ESC[19]. In view of the above reasons, embryonic stem cells are still limited in application.

Induced pluripotent stem cells
Induced pluripotent stem cells (iPSCs) are generated directly from patient’s somatic cells by gene reprogramming, in this way, the differentiated somatic cells could convert into pluripotent stem cells. Since the transplanted iPSCs is derived from the patients, it has an important clinical advantage of avoiding immune rejection[20]. However, it needs a longer time (16-35 days) for reprogramming of adult cells into induced pluripotent stem cells and the differentiation efficiency is very low, which greatly increases the risk of cell mutation during induction[21]. Therefore, because of the oncogenic potential of iPSCs, larger animal and clinical trials may need before it can be translated into effective clinical treatment.

Skeletal muscle stem cells
The unipotent human skeletal muscle stem cells (SkMCSs) are isolated from the MI patients. Autologous transplantation of SkMCSs into the infarcted heart has the advantages in cell isolation, in vitro culture, high survival rate under hypoxic conditions[22], the unipotent to differentiate into contractile cells, without immune rejection, and no moral dilemma. Transplantation of SkMCSs in human and animal models of MI suggests that the beneficial effect of this cell therapy is reducing left ventricule dilation by altering the expression profile of cardiac genes associated with left ventricule remodeling[23,24]. Currently, the biggest obstacle regarding the use of SkMCSs in clinical treatment is that the differentiated SkMCSs do not express gap junction proteins, which can potentially induce arrhythmias in
recipient\footnote{27}. However, this consequence was not proven in the first randomized placebo-controlled study and long-term follow up of the MI patients after skeletal myoblast transplantation\footnote{12,29}. Further large animal model studies and clinical trials of SkMCs therapy may pay more attention to the effect of this therapy on the physiological function of the heart receiving the cells.

**Bone marrow cells**

Bone marrow cells (BMCs) are a kind of cells with the ability of self-renewal, proliferation, and differentiation. BMCs have the potential for multi-directional differentiation and are easy to dissociate\footnote{29}. It can differentiate into cardiomyocytes in the cardiac microenvironment. In recent years, autologous bone marrow stem cell transplantation has become a hotspot in biomedical research because it circumvents the problem of immune rejection and bears no ethical concerns\footnote{28,30}. For patients with myocardial infarction, bone marrow stem cell transplantation can significantly reduce myocardial infarction size, repair necrotic myocardium, and prevent ventricular remodeling, promote angiogenesis, and ultimately improve cardiac function\footnote{12}. Clinical follow-up of Bone marrow transfer to enhance ST-elevation infarct regeneration (BOOST) trial indicated that intracoronary autologous BMC transfer leads to a mid-term improvement in echocardiographic parameters of diastolic function in patients after AMI\footnote{12,24}. Currently, the study of the effect of intracoronary autologous BMC on left ventricular (LV) function within 24 h after successful reperfusion therapy demonstrates that intracoronary delivery of autologous BMC leads to an insignificant improvement in LV function at an early time point (<24 h), but it demonstrates the safety and feasibility of clinically early intracoronary injection of BMC and suggests a vital role of BMC therapy in myocardial salvage and ventricular remodeling\footnote{41}. BMC therapy treated AMI patients displayed a better quality of life (QoL) at 3 and 12 months post-AMI than the control-group patients\footnote{35}. But the above findings stressed the need for long-term confirmation trials and for systematic assessment of cardiac function after BMC treatment.

**Mesenchymal stem cells**

Mesenchymal stem cells (MSCs) are a subset of non-hematopoietic adult stem cells that can be found in bone marrow, adipose tissue, amniotic fluid, liver, lung, spleen, placenta and umbilical cord blood\footnote{30}. The multipotent MSCs are capable of differentiating into many cell types, including myocytes, osteoblasts, chondrocytes and adipocytes\footnote{37}. MSCs can be easily isolated from the tissues of MI patients and expanded in vitro. Previous studies revealed that MSCs transplantation can prevent left ventricular remodeling and improve heart function without significant safety concerns\footnote{38},

Though MSCs showed low cell retention and poor differentiation into cardiomyocytes, it still can enhance angiogenesis, inhibit cardiomyocytes apoptosis and fibrosis, and improve heart function\footnote{12,29}, suggesting that the transplanted MSCs modulate left ventricular remodeling after MI via a potential paracrine mechanism. The paracrine effects are attributed to the regulation of the NF-κB signal pathway by Rap1, and selective inhibition of Rap1 in BM-MSCs showed reduced inflammation and enhanced cell survival that greatly improves heart function recovery following MI\footnote{39}. Salvianolic acid B (Sal B) was reported to attenuate the apoptosis of MSC\footnote{40}, and transplantation of Sal B pretreated MSCs in rats improves cardiac function partly through the paracrine mechanism and promotes the differentiation of MSC toward endothelium cells\footnote{41}. Hepatocyte growth factor (HGF), an important cytokine for angiogenesis, anti-inflammation and anti-apoptosis, was associated with enhanced angiogenesis, less cardiomyocyte apoptosis, increased proliferation of cardiomyocytes, and cardio-protective effects in a mouse MI model\footnote{42}. However, currently the differentiation rate of transplanted bone marrow stem cells is relatively low, the fate of transplanted cells and whether MSCs will affect the function of other normal cells in vivo is not clear. As almost all studies and clinical trials were short-termed, long-term effects and the underlying mechanism of functional benefits remains to be uncovered to meet the clinical standard and government regulations.

**Cardiac stem cells**

With the continuous development of stem cell research, cardiac stem cells (CSCs) have been successfully isolated and identified. Cardiomyocyte stem cells are pluripotent stem cells in the heart and possess the potential to differentiate into various cardiac cells, including myocytes, smooth muscle and endothelial cells\footnote{43}. In animal experiments, cardiac stem cells were injected into the heart of mice with heart disease, and the injected cells directly migrated to the damaged heart tissue, promoted the regeneration of myocardium, and improved the ability of the heart to pump blood\footnote{44}. Multiple types of CSCs have been identified including Islet-1+ cells, Sca-1+ cells, cardiosphere derived cells (CDCs), cardiac mesoangioblasts, cardiac specific side population, and epicardial progenitors\footnote{45-50}. A lot of preclinical researches in both small and large animal models have indicated the potential of CSCs therapy in treating MI (Table 1). Followed by the extensive study of CSCs in animal models, numerous clinical trials also paved the way for CSCs as new promising therapies that worth further exploring and application (Table 1).

**Stem cell-derived exosomes**

Recently, many stem cell types, including ESC, MSCs, and CSCs,
were found to secrete paracrine factors, such as exosomes and exosome-like vesicles[61,62]. Given the high efficiency of exosomes to transport to donor cells, low toxicity, and high stability, it has been considered as a novel stem cell-derived strategies for MI treatment. ESC-derived exosomes from mouse were uncovered to stimulate neovascularization and restore heart function in mouse MI model. Moreover, ESC-derived exosomes were rich in miR-294 which can promote the survival and proliferation of CPCs[63]. Exosomes secreted from mouse MSCs contained a lot of miR-22 that exerted an anti-apoptotic effect on cardiomyocytes, which restored heart function and reduced infarct size in mouse MI model[64]. Exosomes isolated from human CPCs were rich in miR-210, miR-132, and miR-146a-3p, and injection of these exosomes significantly stimulated angiogenesis, suppressed apoptosis, and improved heart function in rat MI model[65]. Therefore, these findings provide persuasive evidence that stem cell-derived exosomes exert beneficial effects on the treatment of MI in animal models. And it can be anticipated that stem cell-derived exosomes will soon be tested clinically as new strategies for heart regeneration therapy in MI treatment.

**CONCLUSION**

In summary, myocardial infarction mainly leads to myocardial ischemic necrosis that will result in death. At present, the treatment of myocardial infarction mainly includes drug therapy, thrombolytic therapy, and percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery. All these treatments can prevent ventricular remodeling, and to some extent, relieve the symptoms of myocardial ischemia, but all of them have some limitations.

In the stem-cell transplantation trials, researchers revealed that the transplanted stem cells, including bone marrow stem cells, inducible pluripotent stem cells, and cardiac stem cells, survived only for a few weeks in the animal model of ischemic heart disease[66]. Various strategies have been tested to overcome the low survival rate of stem cells after transplantation in heart tissue, but due to different measurements were used in these studies, a unified standard that measuring the efficacies of approaches improving cell retention is required to determine the optimal strategy[67]. In addition, human embryonic stem cell (hESC) and inducible functional stem cell (iPSC) lines showed increased frequency of specific gene aberrations, thus, it requires frequent genetic testing of pluripotent stem cells to ensure its stability and clinical safety[68,69]. Therefore, although stem cell transplantation has a bright future, a cautious attitude needs to be maintained towards clinical trials of stem cell transplantation for the treatment of patients with myocardial infarction.

The adult human heart possess limited capacity to generate cardiomyocytes[70]. Along with the growth of age, the regenerative rate of the cardiomyocyte is gradually slow down. At age 25 the annually regenerative rate is approximately 1% and at age 75 the regenerative rate is reduced to 0.45%. Approximately half of the cardiomyocytes are renewed in human life expectancy[71]. But if the human cardiomyocyte has the ability of regeneration, why most of the cardiomyocyte exit the cell cycle? How to use the potential regenerative ability of cardiomyocytes to restore the damaged cardiomyocyte? In clinical trials, the test and application of stem cell transplantation confront with various problems and are hindered by numerous restrictions. The regenerative ability of cardiomyocytes will undoubtedly provide new research direction to the researchers. Coincidentally, it has been found that Akt1 dramatically enhances and expedites the formation of induced cardiac-like myocytes from fibroblasts in the presence of cardiac transcription factors GATA4, Mef2c, Hand2, and Tbx5[72]. In addition, the cardiac side population, the first population of cardiac progenitor cells identified in the adult heart, can differentiate into cardiac lineages in response to cardiac injury, and thus could be a promising target for cardiac regenerative medicine[73]. The research concerning the usage of the regenerative ability of cardiomyocytes for heart regeneration has just started, but many exciting findings have been reported in just a few years. In the near future, these results will be applied to human studies and clinical treatments and bring the gospel to patients with myocardial infarction.

Myocardial regeneration strategy can not only prevent ventricular remodeling, but also repair the necrotic myocardium and provide a fundamental cure for patients with myocardial infarction. But the study of myocardial regeneration has just started. We believe that with the deepening study and discovery of myocardial regeneration, it will become a powerful clinical tool for the treatment of myocardial infarction in the near future.

**REFERENCES**

1. Gonzalez-Cambeiro MC, Lopez-Lopez A, Abu-Assi E, Raposeiras-Roubin S, Pena-Gil C, Garcia-Acuna J, Gonzalez-Juanatey R. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. Rev Port Cardiol. 2016; 16: 30225-30226. [PMID: 27865680]; [DOI: 10.1016/j.repc.2016.07.003]
2. Eyuboglu M. Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients with Myocardial Infarction. *Cardiovasc Drugs Ther.* 2015; 29: 495. [PMID: 26233242]; [DOI: 10.1007/s10557-015-6613-6]

3. Efr F, Dahlem KM, Nia AM, Erdmann E, Wollenberger J, Hellmich M, Kuhr K, Le MT, Herrfurth T, Taghiyev Z, Biesenbach E, Yaksel D, Eran-Ergoknil A, Vanezi M, Caglayan E, Gassanov N. Randomized Control of Sympathetic Drive With Continuous Intravenous Esmolol in Patients With Acute ST-Segment Elevation Myocardial Infarction: The BETA-Blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial. *JACC Cardiovasc Inter.* 2016; 9: 231-240. [PMID: 26847114]; [DOI: 10.1016/j.jcin.2015.10.035]

4. Jariwala P, Chandra S. Diagnosis and management of failed thrombolytic therapy for acute myocardial infarction. *Indian Heart J.* 2010; 62: 21-28. [PMID: 21180030]

5. Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. *Chest.* 2001; 119: 2535-277S. [PMID: 11157653]

6. Omraninava A, Hashemian AM, Masoumi B. Effective Factors in Door-to-Needle Time for Streptokinase Administration in Patients With Acute Myocardial Infarction Admitted to the Emergency Department. *Trauma Mon.* 2016; 21: e19676. [PMID: 27218043]; [DOI: 10.5812/trama.19676]

7. Kunamneni A, Durvasula R. Streptokinase-A Drug for Thrombolytic Therapy: A Patent Review. *Recent Adv Cardiovasc Drug Discov.* 2014; 9: 106-121. [PMID: 26947671]

8. Burien J, Cholín L, Ruiziz M, Dasa O. Intravenous Tissue Plasminogen Activator as Proconvulter of Myocardial Infarction. *Am J Ther.* 2016; [PMID: 27574925]; [DOI: 10.1097/MHT.0000000000000494]

9. Prasad A, Herrmann J. Myocardial infarction due to percutaneous coronary intervention. *N Engl J Med.* 2011; 364: 453-464. [PMID: 21288097]; [DOI: 10.1056/NEJMra0912134]

10. Chang M, Lee AW, JM, Cavalcante R, Sotomi Y, Onuma Y, Matsuura T, Sasaki H, Okada M, Mikoshiba K, Ashraf M. Considerations in Stem Cell Therapy. *Eur Heart J.* 2010; 31: 231-240. [PMID: 26847114]; [DOI: 10.1161/jcircresaha.114.300556]

11. Cai M, Shen R, Song L, Lu M, Wang J, Zhao S, Tang Y, Meng X, Li Z,He ZX. Bone Marrow Mesenchymal Stem Cells (BM-MSCs) Improve Heart Function in Swine Myocardial Infarction Model through Paracrine Effects. *Sci Rep.* 2016; 6: 28250. [PMID: 27321050]; [DOI: 10.1038/srep28250]

12. Chen X, Lu M, Ma N, Yin G, Cui C, Zhan S. Dynamic Tracking of Injected Mesenchymal Stem Cells after Myocardial Infarction: A Serial 7T MRI Study. *Stem Cells Int.* 2016; [PMID: 26565339]. [PMID: 27656215]; [DOI: 10.1155/2016/4656539]

13. Brickwedel J, Gublin H, Reichenspurner H. Long-term follow-up after autologous skeletal myoblast transplantation in ischaemic heart disease. *Interact Cardiovasc Thorac Surg.* 2014; 18: 61-66. [PMID: 24130088]; [DOI: 10.1093/icts/ivt434]

14. Choudry F, Hamshere S, Saunders N, Veerapen I, Bavinbek K, Knight C, Pellerin D, Locca D, Westwood M, Rakhit R, Crake M, Tarkup T, Parmar M, Agrawal S, Bel A, Bruneval P, Cowan C, Pouly J, Mitalipov S, Goudon E, Binder P, Hagege A, Desnos M, Renaud JF, Menasche P, Puceat M. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. *J Clin Invest.* 2016; 132: 1125-1139. [PMID: 25356622]; [DOI: 10.1172/JCI40120]

15. Matsuo Y, Turski H, Okada M, Mikoshiba K, Ashraf M. Adjunctive treatment of myocardial infarction by autologous stem cell transplantation. *Int J Cardiol.* 2016; [PMID: 27540533].

16. Liu W, Wen Y, Bi P, Lai X, Liu X, Kuang S. Hypoxia promotes satellite cell self-renewal and enhances the efficiency of myoblast transplantation. *Development.* 2012, 139: 2857-2865. [PMID: 22764051]; [DOI: 10.1242/dev.079665]

17. Sirmenis R, Kranias K, Asplund SE, BalruthRI, Duval T, Khowske RA, Veshkina E, Reichenhauer H, Schmitz and van Biber B, Cook SM, Palpant NJ, Gantz JA, Rohlfs B, Kolanowski T, Zimna and Stawiski JK. Myoblast transplantation in mice infused heart alters the expression profile of cardiac genes associated with left ventricle remodeling. *Int J Cardiol.* 2016; [PMID: 27226576].

18. Wiernicki B, Rozwadowska N, Malcher A, Kolanowski T, Zimna A, Gowskaya A, Kurpisz M. Human myoblast transplantation in mice infarcted heart alters the expression profile of cardiac genes associated with left ventricle remodeling. *Int J Cardiol.* 2016; [PMID: 27454713]; [DOI: 10.1016/j.ijcard.2015.09.115]

19. Sieczarska A, Chodowska K, Motyl T, Sadowski T. Myogenic cells applications in regeneration of post-infarction cardiac tissue. *J Physiol Pharmacol.* 2013; 64: 401-408. [PMID: 24101386]

20. Menasche P, Attieri O, Janssens S, McKenna W, Reichenhauer H, Trinhaut V, Liboo RN, Palanuel JO, Seymour J, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagege A. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. *Circulation.* 2008; 117: 1189-1200. [PMID: 18285565]; [DOI: 10.1161/CIRCULATIONAHA.107.734103]

21. Yang Y, Li XL, Xue Y, Yang CX, Wang Y, Hu X, Dai Q. Bone marrow cells differentiation into organ cells using stem cell therapy. *Eur Rev Med Pharmacol Sci.* 2016; 20: 2899-2907. [PMID: 27424992]

22. Mansour S. Autologous bone marrow mononuclear stem cells for acute myocardial infarction: is it only about time? *Eur Heart J.*
31. Rangappa S, Makkar R, Forrester J. Review article: current status of myocardial regeneration: new cell sources and new strategies. J Cardiovasc Pharmacol Ther. 2010; 15: 338-343. [PMID: 21098418]; [DOI: 10.1177/1074284910376682]

32. Berry MF, Engler AJ, Woo YJ, Pirioli TJ, Bish LT, Jayasankar V, Morine KJ, Gardner TJ, Discher DE, Sweeney HL. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol. 2006; 290: H2196-2203. [PMID: 16473959]; [DOI: 10.1152/ajpheart.01017.2005]

33. Jiang M, Mao J, He B. The effect of bone marrow-derived cells on diastolic function and exercise capacity in patients after acute myocardial infarction. Stem Cell Res. 2012; 9: 49-57. [PMID: 22640927]; [DOI: 10.1016/j.scr.2012.03.001]

34. Schaefer A, Z Waldo C, Fuchs M, Meyer GP, Lippolt P, Wollert KC, Drexler H. Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial—an echocardiographic study. Eur J Echocardiogr. 2010; 11: 165-171. [PMID: 19946118]; [DOI: 10.1093/ejecho/djp191]

35. Lamirault G, de Bock E, Sebille V, Delasalle B, Roncalli J, Susen S, Piot C, Trochon JN, Teiger E, Neuder Y, Le Tourneau T, Manrique A, Hardouin JB, Lemarchand P. Sustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute cardiac infarction: results from the BONAMI trial. Qual Life Res. 2016; 25: 143-147. [PMID: 10102814]

36. Malgieri A, Kantzari E, Patrizi MP, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med. 2010; 3: 249-269. [PMID: 21072260]

37. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshal DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143-147. [PMID: 10102814]

38. Singh A, Singh A, Sen D. Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015). Stem Cell Res Ther. 2016; 7: 82. [PMID: 27259550]; [DOI: 10.1186/s13287-016-0336-7]

39. Zhang Y, Zhang Z, Gao F, Tse HF, Tergaonkar V, Lian Q. Paracrine regulation in stem cells: the role of Rap1. Cell Death Dis. 2015; 6: e1932. [PMID: 24692366]; [DOI: 10.1038/cddis.2015.285]

40. Bi XB, Deng YB, Gan DH, Wang YZ. Salvianolic acid B promotes survival of transplanted mesenchymal stem cells in spinal cord-injured rats. Acta Pharmacol Sin. 2008; 29: 169-176. [PMID: 18215345]; [DOI: 10.1111/j.1745-724X.2008.00710.x]

41. Guo HD, Cui GH, Tian JX, Lu PP, Zhu QC, Lv R, Shao SJ. Transplantation of salvianolic acid B pretreated mesenchymal stem cells stimulates cardiac function in rats with myocardial infarction through angiogenesis and paracrine mechanisms. Int J Cardiol. 2014; 177: 538-542. [PMID: 25189503]; [DOI: 10.1016/j.ijcard.2014.08.104]

42. Zhao L, Liu X, Zhang Y, Liang X, Ding Y, Xu Y, Fang Z. Enhanced cell survival and paracrine effects of mesenchymal stem cells overexpressing hepatocyte growth factor promote cardioprotection in myocardial infarction. Exp Cell Res. 2016; 344: 30-39. [PMID: 27025401]; [DOI: 10.1016/j.yexcr.2016.03.024]

43. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114: 763-776. [PMID: 14505575]

44. Liu Y, Chen L, Diaz AD, Benham A, Xu X, Wijaya CS, Fa’ak F, Luo W, Soibam B, Azares A, Yu W, Lyu Q, Stewart MD, Gunaratne P, Cooney A, McConnell BK, Schwartz RJ. Mespl Marked Cardiac Progenitor Cells Repair Infarcted Mouse Hearts. Sci Rep. 2016; 6: 31457. [PMID: 27538477]; [DOI: 10.1038/srep31457]

45. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodward S, Lin LZ, Cai CL, Lu MM, Mith M, Platsouy O, Yuan JX, Evans S, Chien KR. Postnatal is1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005; 433: 647-653. [PMID: 15703750]; [DOI: 10.1038/nature0215]

46. Uchida S, De Gaspari P, Kostin S, Jenniches K, Kilic A, Izumiya Y, Shiojima I, Grosse Krembog R, Renz H, Walsh B, Kraut T. Scal-derived cells are a source of myocardial renewal in the murine adult heart. Stem Cell Reports. 2013; 1: 397-410. [PMID: 24286028]; [DOI: 10.1002/stem.2013.09.004]

47. Hensley MT, de Andrade J, Keene B, Meurs K, Tang J, Wang Z, Caranasos TG, Piedrahita J, Li TS, Cheng K. Cardiac regenerative potential of cardiosphere-derived cells from adult dog hearts. J Cell Mol Med. 2015; 19: 1805-1813. [PMID: 25854418]; [DOI: 10.1111/jcmm.12585]

48. Barbuti A, Galvez BV, Crespi A, Scavone A, Baruscotti M, Briosci C, Cossu G, Di Francesco D. Mesoangioblasts from ventricular vessels can differentiate in vitro into cardiac myocytes with synaptic-like properties. J Mol Cell Cardiol. 2010; 48: 415-423. [PMID: 19837079]; [DOI: 10.1016/j.yjmcc.2009.10.006]

49. Oyama T, Nagai T, Wada H, Naito AT, Matsuoka K, Iwakawa N, Takahashi T, Goto M, Mikami Y, Yasuda N, Akazawa H, Uezumi A, Takeda S, Komuro I. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol. 2007; 176: 329-341. [PMID: 17261849]; [DOI: 10.1083/jcb.200603014]

50. Zhou B, Ma Q, Rajagopal S, Wu SM, Domian I, Rivera-Feliciano J, Jiang D, von Gise A, Ikeda S, Chien KR, Pu WT. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature. 2008; 454: 109-113. [PMID: 18568026]; [DOI: 10.1038/nature07060]

51. Suzuki E, Fujita D, Takahashi M, Oba S, Nishimatsu H. Stem cell-derived exosomes as a therapeutic tool for cardiovascular disease. World J Stem Cells. 2016; 8: 297-305. [PMID: 27679686]; [DOI: 10.4252/wjasc.v8.i9.297]

52. Fatima F, Nawaz M. Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy. Chin J Cancer. 2015; 34: 541-553. [PMID: 26369556]; [DOI: 10.1186/s40880-015-0051-0]

53. Khan M, Ma Q, Rajagopal S, Wu SM, Domian I, Rivera-Feliciano J, Jiang D, von Gise A, Ikeda S, Chien KR, Pu WT. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature. 2008; 454: 109-113. [PMID: 18568026]; [DOI: 10.1038/nature07060]
Peng X et al. Novel Treatments for Myocardial Infarction

Stem Cells Int. 2016; 2016: 9682757. [PMID: 26681958]; [DOI: 10.1155/2016/9682757]

58. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV, Lee S, Barrero MJ, Ku S, Martynova M, Semechkin R, Galar V, Gottesfeld J, Izspsua Belmonte JC, Murray C, Keirstead HS, Park HS, Schmidt U, Laslett AL, Muller FJ, Nievergelt CM, Shamir R, Loring JF. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell. 2011; 8: 106-118. [PMID: 21217785]; [DOI: 10.1016/j.stem.2010.12.003]

59. Kang X, Yu Q, Huang Y, Song B, Chen Y, Gao X, He W, Sun X, Fan Y. Effects of Integrating and Non-Integrating Reprogramming Methods on Copy Number Variation and Genomic Stability of Human Induced Pluripotent Stem Cells. PLoS One. 2015; 10: e0131128. [PMID: 26131765]; [DOI: 10.1371/journal.pone.0131128]

60. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zapicich I, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisen J. Evidence for cardiomyocyte renewal in humans. Science. 2009; 324: 98-102. [PMID: 19342590]; [DOI: 10.1126/science.1164680]

61. Zhou H, Dickson ME, Kim MS, Bassel-Duby R, Olson EN. Akt1/2 protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes. Proc Natl Acad Sci U S A. 2011; 112: 11864-11869. [PMID: 26354121]; [DOI: 10.1073/pnas.1516237112]

62. Yellamilli A, van Berlo JH. The Role of Cardiac Side Population Cells in Cardiac Regeneration. Front Cell Dev Biol. 2016; 4: 102. [PMID: 27679798]; [DOI: 10.3389/fcell.2016.00102]

63. Lee ST, White AJ, Matsushita S, Malliaras K, Steenbergen C, Zhang Y, Li TS, Terrovitis J, Yee K, Simsir S, Makkar RR, Marban L, Mendizabal A, Cingolani E, Johnston PV, Gerstenblith S, Bai A, Martinoli E, Carlo E, Balconi G, Fiordaliso F, Chimenti S, Cusella G, Dejana E, Cossu G, Latini R. Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells. Arterioscler Thromb Vasc Biol. 2005; 25: 692-697. [PMID: 15662017]; [DOI: 10.1161/01.ATV.0000156402.52029.ce]

64. Katanaza H, Tseliou E, Malliaras K, Yee K, Dawkins JF, De Couto G, Smith RR, Kreke M, Seinfeld J, Middleton RC, Gallet R, Cheng K, Luthringer D, Valle J, Angert D, Reich H, Luthringer D, Kreke M, Smith R, Marban L, Marban E. Intracoronary delivery of self-assembling heart-derived microtissues (cardiospheres) for prevention of adverse remodeling in a pig model of convalescent myocardial infarction. Circ Cardiovasc Interv. 2015; 8: 49-61. [PMID: 25514633]; [DOI: 10.1161/CIRCINTERVENTIONS.115.002391]

65. Gallici D, Innocenzi A, Staszewsky L, Zaman R, Sampaolesi M, Bhai A, Martinoli E, Carlo E, Balconi G, Fiordaliso F, Chimenti S, Cusella G, Dejana E, Cossu G, Latini R. Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells. Arterioscler Thromb Vasc Biol. 2005; 25: 692-697. [PMID: 15662017]; [DOI: 10.1161/01.ATV.0000156402.52029.ce]

66. Bartolos O, Zhuang ZW, Huang Y, Mikush N, Suh C, Bregasi A, Wang L, Chang W, Krause DS, Young LH, Pober JS, Yang Y. Isl1 cardiovascular progenitor cells for cardiac repair after myocardial infarction. JCI Insight. 2016; 1: [PMID: 27525311]; [DOI: 10.1172/jci.insight.80920]

67. Valiente-Alandi I, Albo-Castellanos C, Herrero D, Sanchez I, Bernad A. Bmi1 (+) cardiac progenitor cells contribute to myocardial repair following acute injury. Stem Cell Res Ther. 2016; 7: 100. [PMID: 27472922]; [DOI: 10.1186/s13287-016-0555-7]

68. Ye J, Boyle A, Shih H, Sievers RE, Zhang Y, Prasad M, Su H, Zhou Y, Grossman W, Bernstein HS, Veggia Zariatos Y. Sca-1+ cardiosphere-derived cells are enriched for Isl1-expressing cardiac precursors and improve cardiac function after myocardial injury. PLoS One. 2012; 7: e30329. [PMID: 22272337]; [DOI: 10.1371/journal.pone.0030329]

69. Gallet R, Tseliou E, Dawkins J, Middleton R, Valle J, Angert D, Reich H, Luthringer D, Kreke M, Smith R, Marban L, Marban E. Intracoronary delivery of self-assembling heart-derived microtissues (cardiospheres) for prevention of adverse remodeling in a pig model of convalescent myocardial infarction. Circ Cardiovasc Interv. 2015; 8: 49-61. [PMID: 25514633]; [DOI: 10.1161/CIRCINTERVENTIONS.115.002391]

70. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, Marban L, Mendizabal A, Cingolani E, Johnston PV, Gerstenblith G, Schuleri KH, Lardo AC, Marban E. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (Cardiosphere-Derived uToligem stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014; 63: 110-122. [PMID: 24036024]; [DOI: 10.1016/j.jacc.2013.08.724]

71. Cheng K, Malliaras K, Smith RR, Shen D, Sun B, Blusztajn A, Xie Y, Ibrahim A, Aminzadeh MA, Liu W, Li TS, De Robertis MA, Marban L, Czer LS, Trento A, Marban E. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail. 2014; 2: 49-61. [PMID: 24511463]; [DOI: 10.1016/j.jchf.2013.08.008]

Peer reviewer: Satoshi Hirohata